PharmTech
CONTINUE TO SITE >

OR WAIT 15 SECS

Patheon Signs Strategic Agreement with Grünenthal

February 22, 2016
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-03-02-2016, Volume 11, Issue 3

Patheon will assist in the development of INTAC, a technology designed to reduce the abuse of controlled substances.

On Feb. 22, 2016 Patheon announced it has signed a strategic agreement with Grünenthal, an international research-based pharmaceutical group headquartered in Aachen, Germany, to serve as its preferred development partner for its products made using Grünenthal’s abuse deterrent formulation technology INTAC.

Patheon was selected to assist with the development of advanced INTAC based products including single-entity and fixed-dose combination solid oral dosage forms with immediate and modified release properties. INTAC is Grünenthal’s proprietary technology designed to reduce the potential for abuse of controlled substances.

INTAC is an abuse-deterrent formulation technology platform, used with several FDA-approved opioid products. As part of the agreement, Grünenthal has agreed to install specialized equipment in Patheon’s Cincinnati manufacturing site. 

Source: Patheon